Home > Boards > US Listed > Medical - Drugs >

Cubist Pharmaceuticals, Inc. (CBST)

CBST RSS Feed
Add CBST Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/14/2019 10:17:20 AM - Followers: 8 - Board type: Free - Posts Today: 0

About Cubist Overview Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that address unmet medical needs in the acute care environment. The company is headquartered in Lexington, Massachusetts. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first IV antibiotic from a class of antiinfectives called lipopeptides. Cubist employs 409 people. The company's total net revenues increased 61% to $194.7 million in 2006 from $120.6 million in 2005. Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that address unmet medical needs. History Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel antiinfectives for use in hospitals and other acute care environments. Cubist completed its initial public offering (IPO) in 1996, and shares are listed on NASDAQ (ticker symbol: CBST). In 1997, at a time when most pharmaceutical companies had abandoned discovery and development of antibiotics, Cubist in-licensed daptomycin, a first-in-class cyclic lipopeptide antibiotic drug candidate, originally discovered by scientists at Eli Lilly, which had discontinued its work on daptomycin as a drug candidate. Based on a breakthrough by Cubist scientists, we resumed human trials with daptomycin in IV form and it was approved by the FDA as CUBICIN (daptomycin for injection) and launched in the U.S. in 2003. CUBICIN has to date experienced the most successful antibiotic launch in U.S. history, on a dollar sales basis. In 2005, Cubist submitted a sNDA seeking an expanded label for CUBICIN based on results of the Company's landmark Phase 3 trial studying the treatment of S.aureus bloodstream infections, including infective endocarditis. Following the positive recommendations of the Anti-infective Drugs Advisory Committee in March 2006, the FDA approved an expanded U.S. label for CUBICIN on May 25, 2006. For information on the expanded label please visit www.cubicin.com Products & Pipeline The promise of Cubist Pharmaceuticals is based on both a current product, CUBICIN® (daptomycin for injection), which represents the most successful IV antibiotic launch, in dollar terms, in U.S. history, as well as on internal discovery and external sourcing of acute care drug candidates. Cubist is continuing research to help optimize knowledge about the utility and advantages of CUBICIN in the infectious disease armamentarium. CUBICIN development includes a Phase 2 high dose short duration (10 mg/kg for 4 days) cSSSI study and a Phase 2 comparative dose (6 and 8 mg/kg) study in prosthetic joint infections. Cubist believes CUBICIN will continue growing (to greater than $750 Million annually in the U.S. alone) with its current labeled indications and has not yet made decisions on the appropriateness of additional registration (Phase 3) studies. The company has a growing early stage pipeline of programs which can leverage Cubist's scientific, clinical and regulatory expertise as well as its proven acute care commercial organization. The company's intent is to continue to build this pipeline using internal discovery, research collaborations, in-licensing and acquisition to maximize the opportunity for a flow of IND filings in the years ahead, thus enabling continued revenue growth beyond CUBICIN, which has patent protection in the U.S. through 2019. Current preclinical programs include research focused on: Gram positive infections including infections in the lung and CDAD; Gram negative infections; and candidates emerging from Natural Products screening. Cubist Pharmaceuticals and Santa Clara-based Ilypsa have entered into a research collaboration to develop a non-antibiotic therapy for Clostridium difficile associated diarrhea (CDAD). Cubist believes CUBICIN will continue growing (to greater than $750 Million annually in the U.S. alone ***Technical Charts With Annotations For CBST:*** http://www.stocktradershq.com/charts/CBST.htm Yahoo Finance news and quotes for CBST: http://finance.yahoo.com/q?s=CBST StockCharts Delayed StockCharts: http://stockcharts.com/def/servlet/SC.web?c=CBST http://cubist.com/
CBST
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#125   $CBST Cantor Raises Cubist Pharmaceuticals Price Target In-Line maytepper 12/11/14 12:01:36 PM
#124   CBST and MRK situation is very strange. KarinCA 12/10/14 09:03:19 PM
#123   $CBST Wedbush Comments On Cubist Pharmaceuticals Following Patent maytepper 12/10/14 11:56:27 AM
#122   Sold over $100. Didn't want them to bring KingDMC 12/09/14 09:36:21 PM
#121   $CBST Wedbush Raises Cubist Price Target On The maytepper 12/09/14 03:53:24 PM
#119   Already made my money here hopped out over KingDMC 12/08/14 06:21:22 PM
#118   $CBST Oppenheimer Comments On Cubist Pharmaceuticals As Merck maytepper 12/08/14 03:11:08 PM
#117   VOLUME beambe 12/08/14 01:05:04 PM
#116   $CBST Cantor Raises Cubist Pharmaceuticals Price Target Following maytepper 12/08/14 11:11:19 AM
#115   Any idea what happens with the $1.0+ shareholder gumbygaya 12/08/14 10:54:44 AM
#114   Congratulations Cubist!!! asmarterwookie 12/08/14 07:57:06 AM
#113   Merck to Acquire Cubist Pharmaceuticals for $102 Per KingDMC 12/08/14 07:05:54 AM
#112   Merck buyout!!! KingDMC 12/08/14 06:33:31 AM
#111   $68 gap had to be filled as previously KingDMC 06/27/14 11:46:07 AM
#110   Looks like 86 plus might be in order Romeo2 06/24/14 11:55:06 PM
#109   Looks like heading to 86 after correction Romeo2 06/23/14 01:36:07 PM
#108   Closing Fridays gap around $68. Looking for re KingDMC 06/23/14 12:09:40 PM
#107   $80 pre market high nice KingDMC 06/23/14 07:28:05 AM
#106   Coverage initiated by Gabelli & Co. = Buy KingDMC 06/22/14 11:07:12 AM
#105   Love it! Wondering where PPS heads to from KingDMC 06/20/14 07:41:40 PM
#104   Approved! Driver70 06/20/14 07:11:28 PM
#103   Approval soon :-) KingDMC 06/20/14 04:58:58 PM
#102   Isnt anybody interested in CBST ? 123tom 04/29/14 04:18:38 PM
#101   11:07AM Cubist Pharma submits Clinical Trial Application to surf1944 01/10/14 02:17:20 PM
#100   Acquisition of Trius Therapeutics -call transcript - ECole 08/01/13 03:50:49 AM
#99   8:27AM On The Wires (WIRES) : Cubist Pharmaceuticals surf1944 07/12/12 09:42:23 AM
#98   9:05AM Cubist Pharma unveils Five-Year strategic goals (CBST) surf1944 06/11/12 10:13:04 AM
#97   <<< $CBST Links! >>> ~ MAC's Quick DD Penny Roger$ 04/18/12 06:11:34 AM
#96   ~ Wednesday! $CBST ~ Q1 Earnings posted, pending Penny Roger$ 04/18/12 06:11:11 AM
#95   Cubist Pharma CBST Oppenheimer Outperform $45 » $49 surf1944 04/04/12 08:19:04 AM
#94   Cubist up after deal with TEVA to mlkrborn 04/05/11 01:21:16 PM
#93   Cubist Pharma CBST Wedbush Neutral » Outperform $25 surf1944 04/05/11 10:40:49 AM
#92   Killing the Superbug: “Owning this stock is like kiwisteve 11/15/10 03:17:18 PM
#91   Cubist Pharmaceuticals(CBST_), however, was lower, trading down 3% mlkrborn 10/14/10 11:44:05 PM
#90   September 12-15 surf1944 09/01/10 07:59:59 PM
#89   CBST Q1 total net revenue up 19% vs JPK1 04/15/10 08:17:56 PM
#88   Cubist (CBST) Proprietary Antibiotics Netting $500 Million Annually surf1944 04/13/10 11:59:24 PM
#87   I sold out of CBST back in Feb, surf1944 04/13/10 11:52:52 PM
#86   Surf...you still here? Interesting developements taking place with JPK1 04/13/10 11:23:58 PM
#85   4:04PM Cubist Pharma misses by $0.03, reports revs surf1944 01/21/10 09:33:58 PM
#84   Going to bust $20 today IMO JPK1 01/14/10 10:36:58 AM
#83   Holding it's own with a down market, looking JPK1 01/13/10 12:34:52 AM
#82   7:08AM Cubist Pharma announces FY09 total net revenue surf1944 01/11/10 09:11:52 AM
#81   Outstanding vs Float [SMART MONEY] 09/06/09 01:09:31 AM
#80   ditto .. fourkids_9pets 09/03/09 02:28:28 PM
#79   Jumped a dollar as soon as Najarian pr'd JPK1 09/03/09 02:06:27 PM
#78   needham analyst fourkids_9pets 06/10/09 03:22:23 PM
#77   moving up from here - keep your eye bcpark 04/03/09 11:08:30 AM
#76   Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's cfoofme 07/02/08 03:44:59 PM
#75   Drug resistant infections rise: cfoofme 05/04/08 05:52:48 PM
PostSubject